Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving anti-hepatitis C virus therapy.

Stanislas Pol1, Vincent O Mallet

  • 1Hôpital Necker, APHP, Unité d'Hépatologie, 149 rue de Sèvres, 75015 Paris Cedex 15, France. stanislas.pol@nck.ap-hop-paris.fr

Expert Opinion on Biological Therapy
|August 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnostic approach for metabolic dysfunction associated steatotic liver disease].

La Revue du praticien·2026
Same author

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Infectious diseases and therapy·2026
Same author

HCV Cure: To Bridge the Gaps in the Care Continuum.

Journal of viral hepatitis·2026
Same author

In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

Cell reports·2025
Same author

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor.

JHEP reports : innovation in hepatology·2025
Same author

Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER).

BMC global and public health·2025
Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
See all related articles

Hepatitis C virus (HCV) infection affects 123 million globally. Advances in diagnosis and treatment have improved outcomes, with current therapies achieving 50% eradication rates, and new treatments promising further success.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Hepatitis C virus (HCV) infection impacts 123 million worldwide, causing significant public health burdens including hepatic and extrahepatic complications.
  • HCV infection diminishes patients' quality of life, necessitating effective management strategies.

Purpose of the Study:

  • To review recent advancements in the diagnosis and treatment of Hepatitis C virus (HCV) infection.
  • To outline improved strategies for screening, evaluating liver impact, and tailoring therapeutic regimens for HCV patients.

Main Methods:

  • Enhanced screening strategies utilizing sensitive serological and virological tests.
  • Improved evaluation of liver disease severity through biopsy, biochemical markers, and elastometry.
  • Tailored therapeutic regimens based on virological and host factors, including genotype, viral kinetics, and fibrosis stage.

Related Experiment Videos

Main Results:

  • Current treatment regimens achieve a 50% rate of complete HCV eradication.
  • Eradication rates vary (45-90%) based on HCV genotype and early viral response.
  • Progress in diagnosis and treatment has refined patient selection, therapy personalization, and monitoring.

Conclusions:

  • Significant progress in HCV diagnosis and treatment has led to improved patient outcomes.
  • Ongoing development of novel therapies, including protease and polymerase inhibitors, holds promise for higher eradication rates and reduced toxicity.
  • Future therapeutic strategies aim to further increase HCV eradication success and improve patient quality of life.